Get the Stockscreener App
0.9562
0.09%
-0.0009
Tela Bio Inc stock is traded at $0.9562, with a volume of 76,557.
It is down -0.09% in the last 24 hours and down -60.65% over the past month.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
See More
Previous Close:
$0.9571
Open:
$0.9366
24h Volume:
76,557
Relative Volume:
0.29
Market Cap:
$39.95M
Revenue:
$63.15M
Net Income/Loss:
$-40.30M
P/E Ratio:
-0.5726
EPS:
-1.67
Net Cash Flow:
$-44.47M
1W Performance:
+1.72%
1M Performance:
-60.65%
6M Performance:
-61.60%
1Y Performance:
-81.50%
1-Day Range:
$0.93
$1.0355
1-Week Range:
$0.8903
$1.07
52-Week Range:
$0.8645
$6.50
Tela Bio Inc Stock (TELA) Company Profile
Name
Tela Bio Inc
Sector
Industry
Phone
484-320-2930
Address
1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA
Compare TELA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELA
Tela Bio Inc
|
0.9562 | 39.95M | 63.15M | -40.30M | -44.47M | -1.67 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Tela Bio Inc Stock (TELA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-31-22 | Initiated | Lake Street | Buy |
| Dec-03-19 | Initiated | Canaccord Genuity | Buy |
| Dec-03-19 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-19 | Initiated | Jefferies | Buy |
| Dec-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Tela Bio Inc Stock (TELA) Latest News
TELA Bio to Announce First Quarter 2025 Financial Results | TELA Stock News - GuruFocus
TELA Bio to Announce First Quarter 2025 Financial Results - GlobeNewswire
TELA Bio, Inc. (NASDAQ:TELA) Stock Position Boosted by Commonwealth Equity Services LLC - Defense World
Prudential Financial Inc. Takes $57,000 Position in TELA Bio, Inc. (NASDAQ:TELA) - Defense World
Tela Bio slumps after Q4 miss as Piper Sandler downgrades - MSN
TELA Bio Expands OviTex PRS Line with Larger Surgical Sizes - MSN
Canaccord maintains TELA Bio stock with $7 target post-challenges By Investing.com - Investing.com Canada
Canaccord maintains TELA Bio stock with $7 target post-challenges - Investing.com
Tela Bio stock plunges to 52-week low of $1.13 amid market challenges - Investing.com Canada
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50% - simplywall.st
TELA Bio introduces larger sizes for soft tissue reconstruction - Investing.com India
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery - GlobeNewswire
Revolutionary Expansion: TELA Bio's New OviTex PRS Sizes Set Industry Record as Sales Surge 31% - Stock Titan
TELA Bio’s Earnings Call: Challenges and Optimism for 2025 - MSN
TELA Bio (NASDAQ:TELA) Cut to “Neutral” at Piper Sandler - The AM Reporter
TELA Bio Announces 2024 Financial Results and Positive 2025 Outlook - MSN
TELA Bio’s SWOT analysis: biologic platform maker faces growth hurdles By Investing.com - Investing.com Canada
Canaccord Genuity Group Lowers TELA Bio (NASDAQ:TELA) Price Target to $7.00 - Defense World
TELA Bio (NASDAQ:TELA) Rating Lowered to “Neutral” at Piper Sandler - Defense World
TELA Bio (NASDAQ:TELA investor three-year losses grow to 88% as the stock sheds US$35m this past week - simplywall.st
TELA Bio Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance
TELA Bio, Inc. (NASDAQ:TELA) Q4 2024 Earnings Call Transcript - Insider Monkey
Tela Bio downgraded to Neutral from Overweight at Piper Sandler - TipRanks
TELA Bio’s SWOT analysis: biologic platform maker faces growth hurdles - Investing.com India
TELA Bio stock price target cut to $7 by Citizens JMP - Investing.com Canada
TELA Bio Inc. (TELA) reports earnings - Quartz
TELA Bio, Inc. SEC 10-K Report - TradingView
Sector Update: Health Care - TradingView
TELA Bio stock plunges to 52-week low of $1.9 amid market challenges - Investing.com India
TELA Bio Shares Drop 43% After Weak Q4 Growth, High Sales Turnover - Yahoo
TELA Bio’s Hold Rating: Challenges in Sales Force Turnover and Financial Outlook - TipRanks
Tela Bio stock falls as Piper downgrades on Q4 miss (TELA) - Seeking Alpha
Earnings To Watch: TELA Bio Inc (TELA) Reports Q4 2024 Result - Yahoo Finance
TELA Bio stock plunges to 52-week low of $1.9 amid market challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Tela Bio Q4 2024 misses earnings, stock drops By Investing.com - Investing.com Australia
Canaccord cuts TELA Bio stock target to $7, maintains Buy By Investing.com - Investing.com South Africa
Canaccord cuts TELA Bio stock target to $7, maintains Buy - Investing.com
Piper Sandler Downgrades TELA Bio to Neutral From Overweight, Adjusts Price Target to $2 From $5 - MarketScreener
Tela Bio earnings missed by $0.01, revenue fell short of estimates - Investing.com India
Tela Bio Inc Stock (TELA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):